Bendamustine Hydrochloride Injection
Product Images NDC 10019-079

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Bendamustine Hydrochloride (NDC 10019-079). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Baxter Healthcare Corporation, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Image 01)

Chemical structure diagram of bendamustine hydrochloride, showing its molecular components and arrangement as related to the active ingredient bendamustine hydrochloride.*

FDA Label Image

Figure 1 (Image 02)

A Kaplan-Meier survival curve chart depicting progression-free survival in months. The chart compares two study treatment groups: bendamustine hydrochloride (solid line) and chlorambucil (dashed line), showing survival distribution function over time up to approximately 45 months.*

FDA Label Image

Representative Vial Label Pane 1 Of 3 (Image 03)

BENDAMUSTINE HYDROCHLORIDE Injection label showing 100 mg/4 mL (25 mg/mL) strength in a multiple-dose vial. The label indicates intravenous use only, with instructions to dilute the dose in a 500 mL admixture before administration. Storage at 2° to 8°C is required. Manufactured by Baxter Healthcare Corporation, product of Germany.*

FDA Label Image

Representative Vial Label Panel 2 Of 3 (Image 04)

A text panel instructing to aseptically withdraw the required dose volume based on 25 mg/mL concentration and transfer immediately to a 500 mL infusion bag of either 0.9% Sodium Chloride Injection or 2.5% Dextrose/0.45% Sodium Chloride Injection. It advises not to use if solid or particulate matter is observed.*

FDA Label Image

Representative Vial Label Panel 3 Of 3 (Image 05)

Bendamustine HCl Injection 100 mg/4 mL (25 mg/mL) label showing the concentration as a concentrate solution that must be diluted prior to administration with a caution note referring to prescribing information for instructions. The label presents the drug as an intravenous injection by Baxter Healthcare Corporation.*

FDA Label Image

Representative Carton Lbl (Image 06)

Packaging label for Bendamustine HCl Injection 100 mg/4 mL (25 mg/mL) intravenous injection. The label states it is sterile, for prescription use only, and provides dilution instructions requiring a 500 mL infusion bag with either 0.9% Sodium Chloride or 2.5% Dextrose/0.45% Sodium Chloride prior to administration. Manufactured for Baxter Healthcare Corporation, Deerfield, IL, USA, product of Germany. The label also includes storage instructions, hazard precautions, and ingredient information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.